Oskar Hansson
Founder at Cell Invent Sweden AB
Profile
Mr. Oskar Hansson is an Investment Associate at Abelco Investment Group and a Scientific Advisor at Cell Invent Sweden AB.
He received his graduate degree from Umea Universitet.
Oskar Hansson active positions
| Companies | Position | Start |
|---|---|---|
Cell Invent Sweden AB
 Cell Invent Sweden AB Miscellaneous Commercial ServicesCommercial Services Cell Invent Sweden AB is a company based in Lund, Sweden that develops new human disease models based on reprogrammed Alzheimer patient cells. The Swedish company is developing phenotype-based screening methods for drug discovery, drug development, and companion diagnostics development. The company was founded in 2019 by Håkan Toresson, Camilla Orbjörn, Lennart Minthon, Oskar Hansson, and Håkan Toresson has been the CEO since 2019. | Founder | 01/01/2019 |
Abelco Investment Group (Private Equity)
 Abelco Investment Group (Private Equity) Investment ManagersFinance Abelco Investment Group (Private Equity) (Abelco Investment Group) is a private equity division of Abelco Investment Group AB. The firm is headquartered in Stockholm, Sweden. | Private Equity Analyst | 01/06/2021 |
Training of Oskar Hansson
| Umea Universitet | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Abelco Investment Group (Private Equity)
Abelco Investment Group (Private Equity) Investment ManagersFinance Abelco Investment Group (Private Equity) (Abelco Investment Group) is a private equity division of Abelco Investment Group AB. The firm is headquartered in Stockholm, Sweden. | Finance |
Cell Invent Sweden AB
Cell Invent Sweden AB Miscellaneous Commercial ServicesCommercial Services Cell Invent Sweden AB is a company based in Lund, Sweden that develops new human disease models based on reprogrammed Alzheimer patient cells. The Swedish company is developing phenotype-based screening methods for drug discovery, drug development, and companion diagnostics development. The company was founded in 2019 by Håkan Toresson, Camilla Orbjörn, Lennart Minthon, Oskar Hansson, and Håkan Toresson has been the CEO since 2019. | Commercial Services |
- Stock Market
- Insiders
- Oskar Hansson
